Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF V600 - mutated melanoma (BRIM7)

Igor Puzanov; Grant McArthur; Rene Gonzalez; Anna Pavlick; Omid Hamid; Thomas F Gajewski; Ming Yin; Jill Fredrickson; Nicholas Choong; Antoni Ribas

首页> 外文期刊>Journal of Translational Medicine >Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF V600 - mutated melanoma (BRIM7)

【24h】

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF V600 - mutated melanoma (BRIM7)

机译：vemurafenib和cobimetinib（MEK抑制剂[GDC-0973]）在晚期BRAF V600突变的黑色素瘤（BRIM7）的IB期IB研究中的更新结果和相关的FDG-PET分析

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Journal of Translational Medicine》 |2014年第1期|共页
作者
Igor Puzanov; Grant McArthur; Rene Gonzalez; Anna Pavlick; Omid Hamid; Thomas F Gajewski; Ming Yin; Jill Fredrickson; Nicholas Choong; Antoni Ribas;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类心脏、血管（循环系）疾病;
关键词

相似文献

外文文献
中文文献

1. Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma [J] . Yibing Yan, Grant McArthur, Omid Hamid, Journal of Translational Medicine . 2014,第SUPPLEMENTa1期

机译：从BRIM7进行的活检和进行中活检的生物标志物分析-维拉非尼和Cobimetinib联合治疗BRAF V600突变的黑色素瘤的1B期试验
2. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma [J] . Ribas Antoni, Daud Adil, Pavlick Anna C., Clinical cancer research: an official journal of the American Association for Cancer Research . 2020,第1期

机译：在Braf-突变体黑素瘤的vemurafenib和Cobimetinib的一期IB学习（Brim7）的延长了5年的后续结果
3. coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF V600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519) [J] . Paolo A Ascierto, Grant A. McArthur, Brigitte Dréno, Journal of Translational Medicine . 2015,第SUPPLEMENTa1期

机译：coBRIM：vemurafenib与vemurafenib + cobimetinib在先前未经治疗的BRAF V600突变阳性，无法切除的局部晚期或转移性黑色素瘤患者中进行的三阶段，双盲，安慰剂对照研究（NCT01689519）
4. Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor GDC-0973) in advanced BRAFV600- mutated melanoma (BRIM7) [O] . Igor Puzanov, Grant McArthur, Rene Gonzalez, 2014

机译：vemurafenib和cobimetinib（MEK抑制剂GDC-0973）在晚期BRAFV600突变的黑色素瘤（BRIM7）的IB期IB研究中的最新结果和相关的FDG-PET分析
5. Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor GDC-0973), in advanced BRAFV600- mutated melanoma (BRIM7) [O] . Igor Puzanov, Grant McArthur, Rene Gonzalez, 2014

机译：vemurafenib和cobimetinib（MEK抑制剂GDC-0973）在晚期BRAFV600突变的黑色素瘤（BRIM7）的IB期IB研究中的最新结果和相关的FDG-PET分析

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF V600 - mutated melanoma (BRIM7)

著录项

引文网络

相似文献

相关主题

期刊订阅